美国食品和药物管理局警告诺沃诺迪斯克公司, 由于迟迟报告与Ozempic和Wegovy相关的死亡和自杀念头. FDA warns Novo Nordisk over delayed reporting of deaths and suicidal thoughts linked to Ozempic and Wegovy.

FDA向诺和诺德发出警告信，原因是其未报告三起患者死亡——其中一例与自杀有关——以及一例与其GLP-1药物司美格鲁肽（Semaglutide）相关的自杀念头病例，该药物用于Ozempic和Wegovy。 The FDA issued a warning letter to Novo Nordisk over failures to report three patient deaths—including one linked to suicide—and a case of suicidal thoughts associated with its GLP-1 drug semaglutide, used in Ozempic and Wegovy. 这些问题是在2025年对该公司的新泽西设施进行检查时发现的,林业发展局强调,及时报告不利事件对公共安全至关重要。 The issues were found during a 2025 inspection of the company’s New Jersey facility, with the FDA stressing that timely adverse event reporting is critical for public safety. 诺沃·诺迪斯克(Novo Nordisk)承认这些担忧,并说它正在处理该机构的调查结果,强调它认真对待安全报告,警告并不意味着药物不安全。 Novo Nordisk acknowledged the concerns and said it is addressing the agency’s findings, emphasizing it takes safety reporting seriously and that the warning does not imply the drugs are unsafe. 美国食品和药物管理局没有找到足够的证据支持自杀行为警告. The FDA did not find sufficient evidence to support boxed warnings for suicidal behavior.